SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

NEXT STORY
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer
PREV STORY
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH

COPENHAGEN, Denmark, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Innovest Global, Inc. Ready to Enter Healthcare Sector, As Global Health Spending Projected to Reach $8.7 Trillion By 2020 – Spotlight Growth

author_avatar
NASDAQ Market News

Indegene strengthens its Pricing, Reimbursement and Market Access capabilities with Medical Marketing Economics, LLC acquisition

author_avatar
NASDAQ Market News